RENAL IMPAIRMENT IS THE MAJOR TOXICITY OF FOSCAVIR. FREQUENT MONITORING OF SERUM CREATININE, WITH DOSE ADJUSTMENT FOR CHANGES IN RENAL FUNCTION, AND ADEQUATE HYDRATION WITH ADMINISTRATION OF FOSCAVIR, IS IMPERATIVE. (See ADMINISTRATION section; Hydration.)
SEIZURES, RELATED TO ALTERATIONS IN PLASMA MINERALS AND ELECTROLYTES, HAVE BEEN ASSOCIATED WITH FOSCAVIR TREATMENT. THEREFORE, PATIENTS MUST BE CAREFULLY MONITORED FOR SUCH CHANGES AND THEIR POTENTIAL SEQUELAE. MINERAL AND ELECTROLYTE SUPPLEMENTATION MAY BE REQUIRED.
FOSCAVIR IS INDICATED FOR USE ONLY IN IMMUNOCOMPROMISED PATIENTS WITH CMV RETINITIS AND MUCOCUTANEOUS ACYCLOVIR-RESISTANT HSV INFECTIONS. (See INDICATIONS and USAGE section.)
FOSCAVIR is the brand name for foscarnet sodium.
FOSCAVIR is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with FOSCAVIR and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS.
Mucocutaneous Acyclovir-Resistant HSV Infections:
FOSCAVIR is indicated for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. SAFETY AND EFFICACY OF FOSCAVIR HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER HSV INFECTIONS (e.g., RETINITIS, ENCEPHALITIS); CONGENITAL OR NEONATAL HSV DISEASE; OR HSV IN NONIMMUNOCOMPROMISED INDIVIDUALS.
Published Studies Related to Foscavir (Foscarnet)
Antiviral therapeutic efficacy of foscarnet in hepatitis B virus infection. [2005.12]
Foscarnet (PFA), a viral DNA polymerase inhibitor, is a clinical agent for herpes viruses. The goal of the study was to evaluate the therapeutic efficacy of PFA in hepatitis B virus (HBV) infection.
Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation. [2011.07.28]
K.The prophylactic PFA regimen was thus safe and it may reduce the risk of limbic encephalitis, but is not considered to be potent enough to prevent HHV-6 reactivation.
Intravitreal foscarnet for the treatment of acyclovir-resistant acute retinal necrosis caused by varicella zoster virus. [2011.06]
PURPOSE: To report of a case of acute retinal necrosis (ARN), successfully treated with intravitreal foscarnet... CONCLUSIONS: Intravitreal foscarnet was efficacious in the treatment of acyclovir-resistant ARN caused by VZV. It may be used as the sole treatment in patients with intolerance to systemic administration.
Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT. [2011.06]
Human herpesvirus-6 (HHV-6) is a major cause of limbic encephalitis with a dismal prognosis after allogeneic hematopoietic SCT (HSCT). A prospective, multicenter study was conducted to assess the safety and efficacy of preemptive therapy with foscarnet sodium (PFA) for the prevention of HHV-6 encephalitis...
Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients. [2011.05.12]
PURPOSE: Combined immunomodulatory and antiviral treatment was administered to three patients with newly diagnosed HIV-associated primary central nervous system lymphoma (PCNSL) in an attempt to improve outcomes... CONCLUSION: Although IL-2, HAART, high-dose AZT and foscarnet are used for other HIV-related conditions, they did not demonstrate benefit in lymphoma remission for 2 HIV- associated PCNSL patients. The third patient went into delayed remission after additional radiotherapy and was in good clinical and neurological health status over 53 months after diagnosis.
Clinical Trials Related to Foscavir (Foscarnet)
A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) [Completed]
To assess the relative efficacy of oral versus intravenous hydration during foscarnet sodium
(Foscavir) induction therapy, as determined by changes in creatinine clearance. To estimate
the timing and volume of oral fluid hydration required to establish a diuresis before and
during intravenous Foscavir therapy. To assess the general tolerance of two hydration
regimens by the adverse event profile associated with each.
Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease [Completed]
PRIMARY: To compare the frequency of and time to relapse of Cytomegalovirus (CMV)
gastrointestinal disease following foscarnet induction therapy only versus induction plus
SECONDARY: To determine frequency of and time to recurrence of gastrointestinal symptoms,
response rate of pathological lesions, and incidence of nongastrointestinal CMV disease in
this patient population.
Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study [Completed]
To determine whether acute ionized hypomagnesemia and hypocalcemia immediately following
foscarnet infusions can be lessened or eliminated by prior infusion of magnesium sulfate. To
determine whether reductions in ionized magnesium, ionized calcium, and parathyroid hormone
levels following foscarnet infusions are lessened by preinfusion of magnesium sulfate. To
evaluate the safety of intravenous magnesium sulfate prior to foscarnet infusion by
monitoring blood pressure, heart rate, and heart rhythm. To characterize the effect of
magnesium sulfate on foscarnet blood levels and urinary excretion of calcium, magnesium,
phosphate, and foscarnet.
The Effect of Stomach Acid on Foscarnet [Completed]
To see if ranitidine, by reducing stomach acidity, can enhance the effectiveness of
foscarnet, by making foscarnet more available to the body.
Foscarnet is an antiviral compound. Laboratory studies have shown it to be active against
HIV. However, only 12 - 22 percent of an oral foscarnet dose is absorbed by the body.
Ranitidine suppresses gastric acid output, increasing gastric pH. Thus by increasing gastric
pH (decreasing stomach acidity), less foscarnet is expected to be decomposed or broken down
in the stomach. Thus, more foscarnet should be absorbed into the body.
An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients [Completed]
To evaluate the safety and efficacy of foscarnet induction therapy for treatment of AIDS
patients experiencing their first episode of cytomegalovirus (CMV) retinitis. To evaluate the
safety and efficacy of three different foscarnet maintenance therapy regimens. To determine
the pharmacokinetics of intermittent administration of foscarnet with or without concomitant
administration of zidovudine (AZT).
Reports of Suspected Foscavir (Foscarnet) Side Effects
Renal Failure Acute (7),
Multi-Organ Failure (6),
Renal Impairment (6),
Septic Shock (5),
Toxic Epidermal Necrolysis (4),
Encephalitis Cytomegalovirus (4),
Cytomegalovirus Infection (4),
Hepatic Function Abnormal (3), more >>
Page last updated: 2011-12-09